Welcome to our dedicated page for Globus Med SEC filings (Ticker: GMED), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a 10-K stuffed with FDA pathways, robotics R&D figures, and post-market surveillance data can feel like surgery without anesthesia. Globus Medical’s disclosures are dense because every new spinal implant or enabling technology must meet strict regulatory standards. If you need those details but not the 300-page headache, you’re in the right place.
Our platform delivers AI-powered summaries that turn each Globus Medical annual report 10-K simplified into a few clear paragraphs. The same engine decodes every Globus Medical quarterly earnings report 10-Q filing, flags revenue swings across musculoskeletal and enabling-technology lines, and translates 8-K device-recall notices into plain English. Want to know when executives buy or sell shares? Instant alerts track Globus Medical insider trading Form 4 transactions and Globus Medical Form 4 insider transactions real-time.
Explore filings by purpose:
- 10-K & 10-Q: R&D spend on robotic navigation, global sales momentum, pipeline timing—Globus Medical earnings report filing analysis
- Form 4: Globus Medical executive stock transactions Form 4 for insight into management sentiment
- 8-K: Globus Medical 8-K material events explained—from FDA approvals to unexpected recalls
- DEF 14A: Globus Medical proxy statement executive compensation showing how leadership is incentivized
Every document is refreshed direct from EDGAR within minutes, so you never miss a filing. With one click you’re understanding Globus Medical SEC documents with AI—saving hours while gaining the confidence to monitor regulatory milestones, compare segment margins, and evaluate insider sentiment without sifting through technical jargon.
Globus Medical (GMED) filed an 8-K announcing immediate executive changes effective 18 Jul 2025. Daniel T. Scavilla resigned as President, CEO and director; the company states the departure is not related to any disagreement on operations or financial matters.
The Board promoted Keith W. Pfeil (46) from COO/CFO to President & CEO and appointed him to the Board and its Nominating & Corporate Governance Committee. Pfeil led the NuVasive integration and multiple corporate functions since joining as CFO in 2019. His compensation rises to a $490k base salary, $900k target bonus (prorated) and an option for 40,000 Class A shares vesting over four years.
Kyle Kline (40), formerly SVP Finance, becomes CFO and principal accounting/financial officer. He will receive a $345k base salary, $200k target bonus and an option for 20,909 shares, also four-year vesting.
An accompanying press release (Ex. 99.1, furnished) includes preliminary Q2 2025 sales figures, but those numbers are not disclosed in this filing. No other material transactions were reported.
FAQ
What is the current stock price of Globus Med (GMED)?
What is the market cap of Globus Med (GMED)?
What does Globus Medical Inc specialize in?
What are the primary product segments of the company?
How does Globus Medical generate its revenue?
What differentiates Globus Medical from its competitors?
Which markets does Globus Medical serve?
How does the company ensure clinical excellence and reliability?
What role do enabling technologies play in Globus Medical's business model?
How does Globus Medical support surgeon education and training?
